Natera
Cell-free DNA assays are changing the way transplant surgeons conduct routine surveillance and steroid weaning.
Natera Enrolls First Patients in HEROES Metastatic HER2+ Breast Cancer Trial
Natera's Signatera test and diagnostic imaging will be used to monitor patients for progression-free survival over the course of one year.
Natera MRD Test Receives MolDx Coverage for Lung Cancer Surveillance
The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.
The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.
Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.